This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


FDA adds warning to Ozempic label about risk for blocked intestines

FDA adds warning to ozempic label about risk for blocked intestines

Ozempic, a type 2 diabetes drug that has increasingly been used to help with weight loss, will now be labeled as having the potential to block intestines.

The U.S. Food and Drug Administration recently made the label update for the drug made by Novo Nordisk, without directly citing Ozempic as the cause for this condition.

"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure," the label reads.

The side effect, known by the medical term "ileus," is also listed on labels for the drug Wegovy, also made by Novo Nordisk, and in the diabetes medication Mounjaro, made by Eli Lilly, CBS News reported.

Both Ozempic and Wegovy are known generically as semaglutide. Among more than 8,500 reports of gastrointestinal disorders after using semaglutide medications through June 30, ileus is mentioned in 33 cases, including two deaths, CBS News reported.

The two that make these medications are both being sued for claims that the drugs can cause a similar health issue known as gastroparesis, or stomach paralysis, CBS News reported.

More information: The U.S. National Library of Medicine has more on ileus.

Copyright © 2023 HealthDay. All rights reserved.

Citation: FDA adds warning to Ozempic label about risk for blocked intestines (2023, September 28) retrieved 2 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Diabetes drug maker sues over compounded versions of Mounjaro


Feedback to editors